论文部分内容阅读
目的:观察125I粒子瘤内植入治疗晚期肺癌的近期疗效,探讨该方法治疗肺癌的临床价值。方法:对22例经病理证实的原发IIIB及IV期非小细胞肺癌患者,CT定位下行肺内病灶放射性粒子植入术。术后1～6个月进行临床随访,术后第3个月后全部行CT复查。结果:1、KPS评分:提高7例,稳定14例,下降1例。2、根据肺癌近期有效率的评定标准,125I粒子瘤内植入有效率(CR+PR)为73.9%(17/23)。3、肿瘤在5cm以下者有效控制率为93.3%,≤3者有效控制率为100%。4、所有病例未出现放射性肺炎、粒子丢失等严重并发症。结论:1、CT导向经皮穿刺瘤内植入125I粒子对晚期肺癌有较好的近期治疗效果,该方法能够提高患者的KPS评分(P<0.05)能够有效缩小肿瘤体积(P<0.05)。
Objective: To observe the short-term curative effect of 125I intracavitary tumor implantation in the treatment of advanced lung cancer and to explore the clinical value of this method in the treatment of lung cancer. Methods: Twenty-two patients with pathologically confirmed primary stage IIIB and IV non-small cell lung cancer underwent CT localization of radioactive intrapulmonary implantation. The patients were followed up 1 to 6 months after operation and all the patients underwent CT examination after the first 3 months. Results: 1, KPS score: improved in 7 cases, stable in 14 cases, decreased in 1 case. According to the recent assessment criteria for lung cancer, the effective rate of intracranial 125I implantation (CR + PR) was 73.9% (17/23). 3, the tumor in the 5cm effective control rate of 93.3%, ≤ 3 effective control rate of 100%. 4, all cases did not appear radiation pneumonitis, particle loss and other serious complications. CONCLUSIONS: 1. The 125I particles implanted in CT guided percutaneous aspiration tumor have good short-term therapeutic effect on advanced lung cancer. The KPS score (P <0.05) can effectively reduce the tumor volume (P <0.05).